Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Samuel D. Riccitelli
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
cancer diagnostics
liquid biopsy |
| gptkbp:founded |
1997
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:offersProduct |
Target Selector
|
| gptkbp:offersService |
molecular diagnostic testing
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
cell-free DNA analysis
circulating tumor cells |
| gptkbp:stockSymbol |
BIOC
|
| gptkbp:website |
https://www.biocept.com/
|
| gptkbp:bfsParent |
gptkb:Sorrento_Mesa
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Biocept
|